Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia

Haematologica

Volumn 89, Issue 5, 2004, Pages 528-540

  Kern, Wolfgang ^a   Voskova, Daniela ^a   Schoch, Claudia ^a   Schnittger, Susanne ^a   Hiddemann, Wolfgang ^a   Haferlach, Torsten ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukemia; Leukemia associated aberrant immunophenotypes; Minimal residual disease; Multiparameter flow cytometry; Prognostic factors

Indexed keywords

CYTARABINE; DAUNORUBICIN; METHOTREXATE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARAMETER; PROGNOSIS; SALVAGE THERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CYTARABINE; DAUNORUBICIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THIOGUANINE;

EID: 2542482696     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciari C, et al. Common themes in the pathogenesis of acute myeloid leukemia. Oncogene 2001;20:5680-94.
2. Buchner T, Hiddemann W, Berdel W, Wormann B, Schoch C, Loffler H, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 2002;6:46-59.
3. Burnett AK. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol 2002;6:26-45.
4. Berman E. Recent advances in the treatment of acute leukemia: 1999. Curr Opin Hematol 2000;7:205-11.
5. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
6. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep 2002;4:390-7.
7. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
8. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
9. Haferlach T, Schoch C, Loffler H, Gassmann W, Kern W, Schnittger S, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256-65.
10. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003;101:64-70.
11. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-5.
12. Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-78.
13. Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998;16:872-81.
14. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
15. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60:454-62.
16. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746-55.
17. Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003;21:4413-22.
18. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443-9.
19. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123:243-52.
20. Kern W, Schnittger S. Monitoring of AML by flow cyometry. Curr Oncol Rep 2003;5:405-12.
21. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746-51.
22. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez Berges C, Gonzalez M, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-70.
23. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948-52.
24. Dugas M, Schoch C, Schnittger S, Kohlmann A, Kern W, Haferlach T, et al. Impact of integrating clinical and genetic information. Int Silico Biol 2002;2:383-91.
25. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
26. Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, Mergenthaler S, et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 2002;99:10008-13.
27. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000;14:1362-70.
28. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-24.
29. Kern W, Haferlach T, Schoch C, Sauerland MC, Heinecke A, Wormann B, et al. Risk-adapted therapy of AML: the AMLCG experience. Ann Hematol 2004;(in press).
30. Buchner T, Urbanitz D, Emmerich B, Fischer JT, Fulle HH, Heinecke A, et al. Multicentre study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res 1982;6:827-31.
31. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen Ant R, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987;69:744-9.
32. Haferlach T, Schoch C, Loffler H, Gassmann W, Schnittger S, Fonatsch C, et al. Cytomorphology and cytogenetics in de novo AML: importance for the definition of biological entities. Blood 1999;94:291a [abstract].
33. Buchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985;3:1583-9.
34. Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb HJ, et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow. Haematologica 2003;88:646-53.
35. Kern W, Kohlmann A, Wuchter C, Schnittger S, Schoch C, Mergenthaler S, et al. Correlation of protein expression and gene expression in acute leukemia. Cytometry 2003;55B:29-36.
36. Haferlach T, Winkemann M, Loffler H, Schoch R, Gassmann W, Fonatsch C, et al. The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization. Blood 1996;87:2459-63.
37. Loffler H, Kayser W, Schmitz N, Thiel E, Hoelzer D, Buchner T, et al. Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany. Hamatol Bluttransfus 1987;30:21-7.
38. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991;78:325-9.
39. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
40. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
41. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002;35:20-9.
42. Schoch C, Kern W, Krawitz P, Dugas M, Schnittger S, Haferlach T, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001;98:3500.
43. Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, Schlegelberger B, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001;112:118-26.
44. Schnittger S, Boell I, Schoch C, Dugas M, Kern W, Sauerland MC, et al. FLT3D835/ 1836 point mutations in acute myeloid leukemia: correlation to cytogenetics, cytomorphology, and prognosis in 1229 patients. Blood 2002;100:329a [abstract].
45. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
46. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958;53:457-81.
47. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90:4710-8.
48. Preisler HD, Priore R, Azarnia N, Barcos M, Raza A, Rakowski I, et al. Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements. Br J Haematol 1986;63:625-36.
49. Hiddemann W, Clarkson BD, Buchner T, Melamed MR, Andreeff M. Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood 1982;59:216-25.
50. Preisler HD. Failure of remission induction in acute myelocytic leukemia. Med Pediatr Oncol 1978;4:275-6.
51. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69-79.
52. Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, et al. Empirical examination of the neutrophil criterion (>1500 &mgr;l(-1)) currently needed to declare CR in AML. Leuk Res 2003; 27: 475-9.
53. Venditti A, Maurillo L, Buccisano F, Tamburini A, Del Poeta G, Del Principe MI, et al. Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Leuk Lymphoma 2003;44:445-50.
54. San Miguel JF, Vidriales MB, Orfao A. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML). Best Pract Res Clin Haematol 2002;15:105-18.
55. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139-52.
56. San Miguel JF, Ciudad J, Vidriales MB, Orfao A, Lucio P, Porwit-MacDonald A, et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol 1999;32:175-85.
57. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993;100:534-40.
58. Elghetany MT, Patel J, Martinez J, Schwab H. CD87 as a marker for terminal granulocytic maturation: assessment of its expression during granulopoiesis. Cytometry 2003;51B:9-13.